Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer

Ma,Bin‑Lin; Shan,Mei‑Hui; Sun,Gang; Ren,Guang‑Hui; Dong,Chao; Yao,Xuemei; Zhou,Mei

doi:10.3892/mmr.2015.4037

Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer

Authors:
- Bin‑Lin Ma
- Mei‑Hui Shan
- Gang Sun
- Guang‑Hui Ren
- Chao Dong
- Xuemei Yao
- Mei Zhou
View Affiliations

Affiliations: Department of Breast and Neck, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China, Department of Epidemiology and Health Statistics, Public Health College of Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China, Department of Pathology, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China
Published online on: July 3, 2015 https://doi.org/10.3892/mmr.2015.4037
Pages: 5246-5254

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate whether the mammalian target of rapamycin (mTOR) signaling pathway is activated in invasive breast cancer. The expression levels of phosphorylated (p)‑mTOR at ser2448 were detected, as well as the expression levels of its downstream signaling molecules: Eukaryotic translation initiation factor 4E‑binding protein 1 (4E‑BP1), and p70 ribosomal protein S6 kinase 1 (S6K1). The correlation between p‑mTOR, p‑4E‑BP1, p‑S6K1, and the clinicopathological parameters of breast cancer were also determined. p‑mTOR, p‑4E‑BP1 and p‑S6K1 expression was detected in 285 breast cancer tumor samples and adjacent normal tissue samples using immunohistochemistry. The expression levels and the location of the proteins were analyzed and compared in the various tissue samples. Multivariate Cox regression was used to analyze the clinicopathological factors and prognosis associated with the tissue samples. The disease‑free survival rate was examined using survival analyses and Log‑rank tests. The results of the present study indicated that the expression levels of p‑mTOR, p‑4E‑BP1, and p‑S6K1 were significantly higher in breast cancer tissue, as compared with normal tissue (P<0.01). p‑mTOR was predominantly expressed in the cytoplasm, whereas p‑4E‑BP1 and p‑S6K1 were predominantly co‑expressed in the cytoplasm and the nucleus. In addition, p‑4E‑BP1 and p‑S6K1 were more likely to be expressed in the cytoplasm in breast cancer tissue samples, as compared with normal tissue samples (P<0.001). Positive p‑mTOR was not significantly correlated with positive p‑4E‑BP1 and p‑S6K1 expression. The survival analyses of the patients with positive p‑mTOR, p‑4E‑BP1, and p‑S6K1 tissue samples were not significantly different from those of the patients with negative tissue samples (P>0.05). Thus suggesting that these markers are not adequate risk factors for disease free survival (P>0.05). In conclusion, the results of the present study suggested that p‑mTOR, p‑4E‑BP1, and p‑S6K1 are activated in invasive breast cancer. In addition, the exclusive expression of p‑4E‑BP1 and p‑S6K1 in the cytoplasm may be characteristic of progressive breast cancer. However, p‑mTOR, p‑4E‑BP1, and p‑S6K1 are not prognostic factors for breast cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Héry C, Ferlay J, Boniol M and Autier P: Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Ann Oncol. 19:1009–1018. 2008. View Article : Google Scholar : PubMed/NCBI
3	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar : PubMed/NCBI
4	den Hollander P, Savage MI and Brown PH: Targeted therapy for breast cancer prevention. Front Oncol. 3:2502013. View Article : Google Scholar : PubMed/NCBI
5	Levi F, Bosetti C, Lucchini F, Negri E and La Vecchia C: Monitoring the decrease in breast cancer mortality in Europe. Eur J Cancer Prev. 14:497–502. 2005. View Article : Google Scholar : PubMed/NCBI
6	Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar : PubMed/NCBI
7	Dai DL, Martinka M and Li G: Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases. J Clin Oncol. 23:1473–1482. 2005. View Article : Google Scholar : PubMed/NCBI
8	Kreisberg JI, Malik SN, Prihoda TJ, et al: Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res. 64:5232–5236. 2004. View Article : Google Scholar : PubMed/NCBI
9	Nakanishi K, Sakamoto M, Yamasaki S, Todo S and Hirohashi S: Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer. 103:307–312. 2005. View Article : Google Scholar
10	Cutler NS, Heitman J and Cardenas ME: TOR kinase homologs function in a signal transduction pathway that is conserved from yeast to mammals. Mol Cell Endocrinol. 155:135–142. 1999. View Article : Google Scholar : PubMed/NCBI
11	Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 441:424–430. 2006. View Article : Google Scholar : PubMed/NCBI
12	Copp J, Manning G and Hunter T: TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): Phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res. 69:1821–1827. 2009. View Article : Google Scholar : PubMed/NCBI
13	Ma XM and Blenis J: Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 10:307–318. 2009. View Article : Google Scholar : PubMed/NCBI
14	Proud CG: Role of mTOR signalling in the control of translation initiation and elongation by nutrients. Curr Top Microbiol Immunol. 279:215–244. 2004.
15	Gera JF, Mellinghoff IK, Shi Y, et al: AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 279:2737–2746. 2004. View Article : Google Scholar
16	Seeliger H, Guba M, Kleespies A, Jauch KW and Bruns CJ: Role of mTOR in solid tumor systems: A therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev. 26:611–621. 2007. View Article : Google Scholar : PubMed/NCBI
17	Yu G, Wang J, Chen Y, et al: Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res. 15:1821–1829. 2009. View Article : Google Scholar : PubMed/NCBI
18	Samuels Y, Wang Z, Bardelli A, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
19	Pérez-Tenorio G, Alkhori L, Olsson B, et al: PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res. 13:3577–3584. 2007. View Article : Google Scholar : PubMed/NCBI
20	Noh WC, Mondesire WH, Peng J, et al: Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res. 10:1013–1023. 2004. View Article : Google Scholar : PubMed/NCBI
21	No JH, Jeon YT, Park IA, et al: Expression of mTOR protein and its clinical significance in endometrial cancer. Med Sci Monit. 15:BR301–BR305. 2009.PubMed/NCBI
22	Meric-Bernstam F and Gonzalez-Angulo AM: Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 27:2278–2287. 2009. View Article : Google Scholar : PubMed/NCBI
23	Lane HA, Wood JM, McSheehy PM, et al: mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res. 15:1612–1622. 2009. View Article : Google Scholar : PubMed/NCBI
24	Yu K, Toral-Barza L, Discafani C, et al: mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer. 8:249–258. 2001. View Article : Google Scholar : PubMed/NCBI
25	Chan S: Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer. Br J Cancer. 91:1420–1424. 2004. View Article : Google Scholar : PubMed/NCBI
26	Georgakis GV and Younes A: From Rapa Nui to rapamycin: Targeting PI3K/Akt/mTOR for cancer therapy. Expert Rev Anticancer Ther. 6:131–140. 2006. View Article : Google Scholar
27	O'Reilly KE, Rojo F, She QB, et al: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66:1500–1508. 2006. View Article : Google Scholar : PubMed/NCBI
28	Heinonen H, Nieminen A, Saarela M, et al: Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. BMC Genomics. 9:3482008. View Article : Google Scholar : PubMed/NCBI
29	Dillon RL, White DE and Muller WJ: The phosphatidyl inositol 3-kinase signaling network: Implications for human breast cancer. Oncogene. 26:1338–1345. 2007. View Article : Google Scholar : PubMed/NCBI
30	Bose S, Chandran S, Mirocha JM and Bose N: The Akt pathway in human breast cancer: A tissue-array-based analysis. Mod Pathol. 19:238–245. 2006. View Article : Google Scholar
31	Bakarakos P, Theohari I, Nomikos A, et al: Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas. Histopathology. 56(8): 76–88. 2010. View Article : Google Scholar
32	Mondesire WH, Jian W, Zhang H, et al: Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res. 10:7031–7042. 2004. View Article : Google Scholar : PubMed/NCBI
33	Zeng Q, Yang Z, Gao YJ, et al: Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: An in vivo bioluminescence imaging study. Eur J Cancer. 46:1132–1143. 2010. View Article : Google Scholar : PubMed/NCBI
34	Volinsky N, McCarthy CJ, von Kriegsheim A, et al: Signalling mechanisms regulating phenotypic changes in breast cancer cells. Biosci Rep. 35:e001782015. View Article : Google Scholar : PubMed/NCBI
35	Li G, Shan C, Liu L, et al: Tanshinone IIA inhibits HIF-1α and VEGF expression in breast cancer cells via mTOR/p70S6K/RPS6/4E-BP1 signaling pathway. PLoS One. 10:e01174402015. View Article : Google Scholar
36	Wang L, Wu J, Lu J, Ma R, Sun D and Tang J: Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines. Mol Med Rep. 11:931–939. 2015.
37	Remmele W and Stegner HE: Recommendation for uniform defnition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:138–140. 1987.In German. PubMed/NCBI
38	Ueng SH, Chen SC, Chang YS, et al: Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas. Int J Clin Exp Pathol. 5:806–813. 2012.PubMed/NCBI
39	Rojo F, Najera L, Lirola J, et al: 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res. 13:81–89. 2007. View Article : Google Scholar : PubMed/NCBI
40	Jacinto E and Hall MN: Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol. 4:117–126. 2003. View Article : Google Scholar : PubMed/NCBI
41	Bachmann RA, Kim JH, Wu AL, Park IH and Chen J: A nuclear transport signal in mammalian target of rapamycin is critical for its cytoplasmic signaling to S6 kinase 1. J Biol Chem. 281:7357–7363. 2006. View Article : Google Scholar : PubMed/NCBI
42	Korkolopoulou P, Levidou G, El-Habr EA, et al: Phosphorylated 4E-binding protein 1 (p-4E-BP1): A novel prognostic marker in human astrocytomas. Histopathology. 61:293–305. 2012. View Article : Google Scholar : PubMed/NCBI
43	Zhang X, Shu L, Hosoi H, Murti KG and Houghton PJ: Predominant nuclear localization of mammalian target of rapamycin in normal and malignant cells in culture. J Biol Chem. 277:28127–28134. 2002. View Article : Google Scholar : PubMed/NCBI
44	Rong L, Livingstone M, Sukarieh R, et al: Control of eIF4E cellular localization by eIF4E-binding proteins, 4E-BPs. RNA. 14:1318–1327. 2008. View Article : Google Scholar : PubMed/NCBI
45	Vega F, Medeiros LJ, Leventaki V, et al: Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res. 66:6589–6597. 2006. View Article : Google Scholar : PubMed/NCBI
46	Li XY, Zhang LQ, Zhang XG, et al: Association between AKT/mTOR signalling pathway and malignancy grade of human gliomas. J Neurooncol. 103:453–458. 2011. View Article : Google Scholar
47	Xiao L, Wang YC, Li WS and Du Y: The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: An immunohistochemical study on tissue microarray. J Exp Clin Cancer Res. 28:1522009. View Article : Google Scholar : PubMed/NCBI
48	Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C and Avruch J: Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem. 273:14484–14494. 1998. View Article : Google Scholar : PubMed/NCBI
49	Weng QP, Kozlowski M, Belham C, Zhang A, Comb MJ and Avruch J: Regulation of the p70 S6 kinase by phosphorylation in vivo. Analysis using site-specific anti-phosphopeptide antibodies. J Biol Chem. 273:16621–16629. 1998. View Article : Google Scholar : PubMed/NCBI
50	Sarbassov DD, Guertin DA, Ali SM and Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
51	Chaux A, Albadine R, Schultz L, et al: Dysregulation of the mammalian target of rapamycin pathway in chromophobe renal cell carcinomas. Hum Pathol. 44:2323–2330. 2013. View Article : Google Scholar : PubMed/NCBI
52	Darb-Esfahani S, Faggad A, Noske A, et al: Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: Association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol. 135:933–941. 2009. View Article : Google Scholar
53	Annovazzi L, Mellai M, Caldera V, Valente G, Tessitore L and Schiffer D: mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma. Anticancer Res. 29:3087–3094. 2009.PubMed/NCBI
54	van der Hage JA, van den Broek LJ, Legrand C, et al: Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br J Cancer. 90:1543–1550. 2004. View Article : Google Scholar : PubMed/NCBI
55	Zhou L, Huang Y, Li J and Wang Z: The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol. 27:255–261. 2010. View Article : Google Scholar
56	Zhou X, Tan M, Stone Hawthorne V, et al: Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res. 10:6779–6788. 2004. View Article : Google Scholar : PubMed/NCBI
57	Pelloski CE, Lin E, Zhang L, et al: Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res. 12:3935–3941. 2006. View Article : Google Scholar : PubMed/NCBI
58	Chakravarti A, Zhai G, Suzuki Y, et al: The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol. 22:1926–1933. 2004. View Article : Google Scholar : PubMed/NCBI
59	Ermoian RP, Kaprealian T, Lamborn KR, et al: Signal transduction molecules in gliomas of all grades. J Neurooncol. 91:19–26. 2009. View Article : Google Scholar